Význam nádorového supresoru p53 u chronické lymfocytární leukemie.
| Title in English | The role of TP53 gene in chronic lymphocytic leukemia. |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Transfuze a hematologie dnes |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | ATM; chronic lymphocytic leukemia; prognostic factors; TP53 |
| Description | The p53 protein is a key cell cycle regulator that protects cells from genotoxic and oncogenic stress and plays a crucial role in preventing cancer development. Even a loss of one allele predisposes the cell to malignant transformation and p53 proteins with missense mutations can adopt novel oncogenic properties. In chronic lymphocytic leukemia (CLL)the TP53 abnormalities occur with a relatively low frequency (10-15%), however they are of a high prognostic impact. Patients with p53defects suffer from aggressive disease and are often resistant to standard chemotherapy. Novel therapeutic approaches acting independently on the p53 pathway are recently available. The TP53 gene is usually impaired by deletion of one and mutation of the other allele, however, relatively large cohort of patients bears only mutations and separate mutations have negative impact on patients survival that is not significantly different from patients with complete p53 inactivation. P53 abnormalities can occur during the course of the disease and therapy plays an important role in their selection. |